glp-1 smoking Ozempic for Addiction? GLP-1s May Reduce Cravings for Alcohol New research: GLP-1 receptor agonists

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

Most are administered via subcutaneous injection, with dosing frequencies ranging from daily to weekly depending on the specific formulation

Tissues were homogenized in cold RIPA lysis buffer (Beyotime, Shanghai, China) containing phenylmethylsulfonyl fluoride (PMSF, Beyotime, Shanghai, China) at 4 C for 1 h

:

Thus, while it is a reasonably safe amino acid to supplement with, like everything else, there is a maximum dose

Nature 486 , S7S9 (2012)